U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07654634) titled 'Precision Antithrombotic Therapy' on May 18.
Brief Summary: The goal of this observational study is to systematically analyze the relationship between trough/peak concentrations of novel oral anticoagulants (NOACs) and antiplatelet drugs with clinical events, aiming to provide high-level evidence for therapeutic drug monitoring (TDM) and personalized dosing.The main questions it aims to answer are:
* What are the optimal preventive and therapeutic concentration ranges for different NOACs (rivaroxaban, apixaban, dabigatran, edoxaban) and antiplatelet drugs (aspirin, indobufen)?
* What are the key factors influencing the blood drug ...